LOAD MORE
You're viewed 45 of 48 products
Remdesivir
References
FAQ's
References
- Chun, Byoung Kwon; Clarke, Michael O' Neil Hanrahan; Doerffler, Edward; Hui, Hon Chung; Jordan, Robert; Mackman, Richard L.; Parrish, Jay P.; Ray, Adrian S.; Siegel, Dustin, Methods For Treating Filoviridae Virus Infections, Gilead Sciences, Inc., United States, EP3366295B1, January 22, 2020
- Alvarez, Jean-Claude; Moine, Pierre; Etting, Isabelle; Annane, Djillali; Larabi, Islam Amine, Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient, Clinical Chemistry and Laboratory Medicine, Volume: 58, Issue: 9, Pages: 1461-1468, 2020
Frequently Asked Questions
What is the potential source of Remdesivir impurities in the synthesis process?
The potential sources of Remdesivir impurities in the synthetic process include starting materials, reagents, intermediates, and degradation products.
How are Remdesivir impurities managed during the storing and distribution process?
Remdesivir impurities are managed during the storing and distribution process through strict quality control measures, proper storage conditions, and adherence to regulatory guidelines to ensure drug integrity, purity, and stability.
Are Remdesivir impurities evaluated during clinical trials?
Yes, impurities in Remdesivir are evaluated during clinical trials to ensure the safety and efficacy of the medication.
What are the temperature conditions required to store Remdesivir impurities?
Remdesivir impurities should be stored at a controlled room temperature between 2-8°C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.
